Literature DB >> 20166103

Androgens, growth factors, and risk of prostate cancer: the Multiethnic Cohort.

Jasmeet K Gill1, Lynne R Wilkens, Michael N Pollak, Frank Z Stanczyk, Laurence N Kolonel.   

Abstract

BACKGROUND: Androgens and growth factors are thought to be associated with prostate cancer risk, although past research has produced mixed results.
METHODS: We conducted a nested case-control study of biomarkers of prostate cancer risk within the Multiethnic Cohort. We compared prediagnostic levels of testosterone, dihydrotestosterone (DHT), sex hormone-binding globulin (SHBG), 3alpha-androstanediol glucuronide (3alpha-diol G), insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein 1 (IGFBP-1), and IGFBP-3 in serum from 467 incident prostate cancer cases and 934 cancer-free controls. Controls were matched to the cases on geographic site (HI, LA), ethnicity, age at specimen collection (+/-1 year), date (+/-1 month) and time of day (+/-2 hr) of sample collection, and fasting status (<6, 6-7, 8-9, >10 hr). Multivariate conditional logistic regression models were used to compute adjusted odds ratios (ORs) and 95% confidence intervals (CIs).
RESULTS: Serum concentrations of testosterone, DHT, SHBG, 3alpha-diol G, IGF-I, IGF-II, IGFBP-1, and IGFBP-3 were not associated with risk of prostate cancer. Tests for trend of quartiles of serum concentrations also did not show any association. Results were relatively unchanged for men with advanced prostate cancer and their matched controls. However, the follow-up period was relatively short (mean of 1.9 years). Analysis by ethnic group showed an increased risk for Latino men in the second (OR = 3.67, 95% CI: 1.63-8.24) and third (OR = 2.96, 95% CI: 1.19-7.40) tertiles of IGF-I serum levels compared with the first tertile.
CONCLUSIONS: The suggested increased risk for IGF-I in Latino men merits further study, with greater statistical power.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20166103      PMCID: PMC2860643          DOI: 10.1002/pros.21125

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  26 in total

1.  Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study.

Authors:  J V Lacey; A W Hsing; C M Fillmore; S Hoffman; K J Helzlsouer; G W Comstock
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-10       Impact factor: 4.254

2.  Insulin-like growth factors and risk of benign prostatic hyperplasia.

Authors:  Anand P Chokkalingam; Yu-Tang Gao; Jie Deng; Frank Z Stanczyk; Isabell A Sesterhenn; F K Mostofi; Joseph F Fraumeni; Ann W Hsing
Journal:  Prostate       Date:  2002-07-01       Impact factor: 4.104

3.  Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States).

Authors:  Chiaojung J Tsai; Barbara A Cohn; Piera M Cirillo; David Feldman; Frank Z Stanczyk; Alice S Whittemore
Journal:  Cancer Causes Control       Date:  2006-12       Impact factor: 2.506

4.  A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.

Authors:  L N Kolonel; B E Henderson; J H Hankin; A M Nomura; L R Wilkens; M C Pike; D O Stram; K R Monroe; M E Earle; F S Nagamine
Journal:  Am J Epidemiol       Date:  2000-02-15       Impact factor: 4.897

5.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.

Authors:  June M Chan; Meir J Stampfer; Jing Ma; Peter Gann; J Michael Gaziano; Michael Pollak; Edward Giovannucci
Journal:  J Natl Cancer Inst       Date:  2002-07-17       Impact factor: 13.506

6.  Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States).

Authors:  Li Li; Herbert Yu; Fredrick Schumacher; Graham Casey; John S Witte
Journal:  Cancer Causes Control       Date:  2003-10       Impact factor: 2.506

7.  Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.

Authors:  Karen Woodson; Joseph A Tangrea; Michael Pollak; Terry D Copeland; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

8.  Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.

Authors:  Chu Chen; Noel S Weiss; Frank Z Stanczyk; S Kay Lewis; Dante DiTommaso; Ruth Etzioni; Matt J Barnett; Gary E Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-12       Impact factor: 4.254

9.  5 alpha-Reductase activity in the genital skin of hirsute women.

Authors:  P Serafini; F Ablan; R A Lobo
Journal:  J Clin Endocrinol Metab       Date:  1985-02       Impact factor: 5.958

10.  High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study.

Authors:  Pär Stattin; Sonja Lumme; Leena Tenkanen; Henrik Alfthan; Egil Jellum; Göran Hallmans; Steinar Thoresen; Timo Hakulinen; Tapio Luostarinen; Matti Lehtinen; Joakim Dillner; Ulf-Håkan Stenman; Matti Hakama
Journal:  Int J Cancer       Date:  2004-01-20       Impact factor: 7.396

View more
  18 in total

1.  Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Authors:  Douglas K Price; Cindy H Chau; Cathee Till; Phyllis J Goodman; Robin J Leach; Teresa L Johnson-Pais; Ann W Hsing; Ashraful Hoque; Howard L Parnes; Jeannette M Schenk; Catherine M Tangen; Ian M Thompson; Juergen K V Reichardt; William D Figg
Journal:  Cancer       Date:  2016-05-10       Impact factor: 6.860

2.  Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer cells treated with sexual hormones and flutamide.

Authors:  Da Yue Tong; Xin yao Wu; Hong yu Sun; Yi Jin; Zhuo wei Liu; Fang jian Zhou
Journal:  Tumour Biol       Date:  2012-08-31

3.  Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.

Authors:  Yin Cao; Katharina Nimptsch; Irene M Shui; Elizabeth A Platz; Kana Wu; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2014-11-10       Impact factor: 7.396

4.  Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism.

Authors:  Ada Lee; Katya Rubinow; Richard V Clark; Ralph B Caricofe; Mark A Bush; Hui Zhi; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2011-08-25

5.  Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model.

Authors:  Ashley Gray; William J Aronson; R James Barnard; Hemal Mehta; Junxiang Wan; Jonathan Said; Pinchas Cohen; Colette Galet
Journal:  J Endocrinol       Date:  2011-09-08       Impact factor: 4.286

6.  Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride.

Authors:  M Y Roth; R E Dudley; L Hull; A Leung; P Christenson; C Wang; R Swerdloff; J K Amory
Journal:  Int J Androl       Date:  2010-10-24

7.  Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition.

Authors:  Alison J Price; Naomi E Allen; Paul N Appleby; Francesca L Crowe; Ruth C Travis; Sarah J Tipper; Kim Overvad; Henning Grønbæk; Anne Tjønneland; Nina Føns Johnsen; Sabina Rinaldi; Rudolf Kaaks; Annie Lukanova; Heiner Boeing; Krasimira Aleksandrova; Antonia Trichopoulou; Dimitrios Trichopoulos; George Andarakis; Domenico Palli; Vittorio Krogh; Rosario Tumino; Carlotta Sacerdote; H Bas Bueno-de-Mesquita; Marcial V Argüelles; Maria-José Sánchez; Maria-Dolores Chirlaque; Aurelio Barricarte; Nerea Larrañaga; Carlos A González; Pär Stattin; Mattias Johansson; Kay-Tee Khaw; Nick Wareham; Marc Gunter; Elio Riboli; Timothy Key
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-07-03       Impact factor: 4.254

8.  Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).

Authors:  Konstantinos K Tsilidis; Ruth C Travis; Paul N Appleby; Naomi E Allen; Sara Lindström; Demetrius Albanes; Regina G Ziegler; Marjorie L McCullough; Afshan Siddiq; Aurelio Barricarte; Sonja I Berndt; H Bas Bueno-de-Mesquita; Stephen J Chanock; E David Crawford; W Ryan Diver; Susan M Gapstur; Edward Giovannucci; Fangyi Gu; Christopher A Haiman; Richard B Hayes; David J Hunter; Mattias Johansson; Rudolf Kaaks; Laurence N Kolonel; Peter Kraft; Loic Le Marchand; Kim Overvad; Silvia Polidoro; Elio Riboli; Fredrick R Schumacher; Victoria L Stevens; Dimitrios Trichopoulos; Jarmo Virtamo; Walter C Willett; Timothy J Key
Journal:  Int J Cancer       Date:  2013-02-15       Impact factor: 7.396

9.  Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.

Authors:  Cindy Ke Zhou; Frank Z Stanczyk; Muhannad Hafi; Carmela C Veneroso; Barlow Lynch; Roni T Falk; Shelley Niwa; Eric Emanuel; Yu-Tang Gao; George P Hemstreet; Ladan Zolfghari; Peter R Carroll; Michael J Manyak; Isabell A Sesterhenn; Paul H Levine; Ann W Hsing; Michael B Cook
Journal:  Prostate       Date:  2017-10-02       Impact factor: 4.104

10.  Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.

Authors:  Jeannette M Schenk; Cathee Till; Ann W Hsing; Frank Z Stanczyk; Zhihong Gong; Marian L Neuhouser; Juergen K Reichardt; Ashraful M Hoque; William D Figg; Phyllis J Goodman; Catherine M Tangen; Ian M Thompson
Journal:  Cancer Causes Control       Date:  2015-11-20       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.